Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose nearly 6%. Recently, a new drug project for solid tumor immune cell therapy was included in a major national science and technology project

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose nearly 6%. As of press release, it had risen 5.94% to HK$16.23, with a turnover of HK$18.8074 million.

According to news, on December 30, according to Keji Pharmaceutical's official WeChat account, the company announced that the “Key Technology and Innovative Drug Research and Development of Immune Cell Therapy for Solid Tumors” project led by its subsidiary Shanghai Keji Pharmaceutical Co., Ltd. was officially approved to be included in the 2025 annual project list for major national science and technology projects for innovative drug research and development. According to reports, major national science and technology projects are China's highest-level scientific research plans in strategic frontier fields. The aim is to achieve independent breakthroughs in key core technologies and industrial transformation.

According to reports, the direction of “research and development of novel drugs for immune cell therapy for solid tumors” to which this project belongs will address clinical and scientific bottlenecks existing in solid tumor treatment and systematically promote innovation and technical research at the source of next-generation immune cell therapy. The project will focus on the cutting-edge field of immune cell therapy for solid tumors, focus on developing breakthrough treatment technologies and innovative products, and promote clinical transformation and engineering preparation systems for related drugs.